Vor Biopharma (NASDAQ:VOR) Price Target Raised to $52.00

Vor Biopharma (NASDAQ:VOR) had its target price lifted by investment analysts at HC Wainwright to $52.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 106.60% from the stock’s previous close. HC Wainwright also issued estimates for Vor Biopharma’s Q3 2025 earnings at ($3.98) EPS, Q4 2025 earnings at ($3.63) EPS, FY2025 earnings at $182.45 EPS, Q1 2026 earnings at ($3.53) EPS, Q2 2026 earnings at ($3.56) EPS, Q3 2026 earnings at ($3.60) EPS, Q4 2026 earnings at ($0.95) EPS, FY2026 earnings at ($8.41) EPS, FY2027 earnings at ($3.91) EPS, FY2028 earnings at $0.50 EPS and FY2029 earnings at $3.21 EPS.

Other analysts have also issued reports about the stock. Zacks Research lowered shares of Vor Biopharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, October 8th. Baird R W raised shares of Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research note on Wednesday, September 24th. Finally, Robert W. Baird upgraded shares of Vor Biopharma from a “neutral” rating to an “outperform” rating and upped their price target for the company from $20.00 to $64.00 in a research note on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $76.50.

Vor Biopharma Stock Performance

VOR traded up $0.17 during trading hours on Wednesday, hitting $25.17. 67,737 shares of the company’s stock were exchanged, compared to its average volume of 393,059. Vor Biopharma has a 1-year low of $2.62 and a 1-year high of $65.80. The firm has a 50-day moving average price of $34.14. The company has a market capitalization of $172.52 million, a PE ratio of -0.09 and a beta of 2.07.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Insider Activity at Vor Biopharma

In related news, Director Ra Capital Management, L.P. sold 24,579 shares of Vor Biopharma stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $25.12, for a total transaction of $617,424.48. Following the sale, the director directly owned 779,652 shares of the company’s stock, valued at approximately $19,584,858.24. The trade was a 3.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of Vor Biopharma stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $30.05, for a total transaction of $349,060.80. Following the sale, the insider owned 1,167,109 shares in the company, valued at approximately $35,071,625.45. This represents a 0.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,431,718 shares of company stock worth $62,090,254 over the last ninety days. 0.45% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its stake in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Vor Biopharma in the 2nd quarter valued at $66,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Vor Biopharma in the 1st quarter valued at $100,000. Jane Street Group LLC bought a new stake in shares of Vor Biopharma in the 1st quarter valued at $140,000. Finally, Ariose Capital Management Ltd bought a new stake in shares of Vor Biopharma in the 3rd quarter valued at $5,368,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.